JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

Начало・Списък с акции・Allogene Therapeutics Inc

Allogene Therapeutics Inc

Затворен

СекторЗдравеопазване

1.69 3.68

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.6800000000000002

Максимум

1.72

Ключови измерители
By Trading Economics
Приходи	9.5M -41M
Служители	226
EBITDA	19M -38M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+431.9% upside

Дивиденти
By Dow Jones
Следващи печалби	12.03.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	158M 420M
Предишно отваряне	-1.99
Предишно затваряне	1.69

Настроения в новините

By Acuity

50%

151 / 352 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

1.18 / 1.69 Подкрепа & съпротива

Allogene Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

6.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

6.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

6.02.2026 г., 21:40 ч. UTC

Придобивния, сливания и поглъщания

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

6.02.2026 г., 21:22 ч. UTC

Пазарно говорене

Mexico's Inflation Seen Accelerating in January -- Market Talk

6.02.2026 г., 21:17 ч. UTC

Печалби

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6.02.2026 г., 21:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

6.02.2026 г., 21:14 ч. UTC

Придобивния, сливания и поглъщания

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

6.02.2026 г., 21:13 ч. UTC

Печалби

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

6.02.2026 г., 21:13 ч. UTC

Печалби

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

6.02.2026 г., 21:04 ч. UTC

Пазарно говорене

Gold Closes Out Volatile Week on Higher Note -- Market Talk

6.02.2026 г., 20:34 ч. UTC

Печалби

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

6.02.2026 г., 20:27 ч. UTC

Печалби

These Stocks Are Today's Movers: Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More -- Barrons.com

6.02.2026 г., 20:24 ч. UTC

Пазарно говорене

Oil Futures Settle Higher As U.S.-Iran Talks Get Under Way -- Market Talk

6.02.2026 г., 20:20 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Retreat Ahead of Weekend -- Market Talk

6.02.2026 г., 19:48 ч. UTC

Печалби

Take-Two, Mondelez Get Analyst Attention -- Barrons.com

6.02.2026 г., 19:30 ч. UTC

Придобивния, сливания и поглъщания

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- WSJ

6.02.2026 г., 19:30 ч. UTC

Придобивния, сливания и поглъщания

Justice Department Asking Industry How Netflix or Paramount Deal for Warner Bros. Might Impact Competition, According to Subpoena -- WSJ

6.02.2026 г., 19:30 ч. UTC

Придобивния, сливания и поглъщания

DOJ Asking if Netflix Engaged in 'Exclusionary Conduct' That May Lead to Monopoly, According to Subpoena -- WSJ

6.02.2026 г., 19:17 ч. UTC

Пазарно говорене

USDA Says Farm Income to Decrease in 2026 -- Market Talk

6.02.2026 г., 18:50 ч. UTC

Печалби

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6.02.2026 г., 18:47 ч. UTC

Пазарно говорене

Natural Gas-Infrastructure Operators Take 'Flight to Scale' -- Market Talk

6.02.2026 г., 18:34 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises By 1 to 412 -- Market Talk

6.02.2026 г., 17:58 ч. UTC

Печалби

Reddit Stock Falls After Strong Earnings. Wall Street Is Debating What's Next. -- Barrons.com

6.02.2026 г., 17:52 ч. UTC

Пазарно говорене

Печалби

Global Equities Roundup: Market Talk

6.02.2026 г., 17:52 ч. UTC

Пазарно говорене

Печалби

Amazon's CapEx Seen as Misunderstood by Investors -- Market Talk

6.02.2026 г., 17:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

6.02.2026 г., 17:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

6.02.2026 г., 17:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

6.02.2026 г., 17:18 ч. UTC

Пазарно говорене

Canada's Bizarre Jobs Report Points to Growing Labor Slack -- Market Talk

6.02.2026 г., 17:09 ч. UTC

Пазарно говорене

Dollar on Path to Snap Weekly Losing Streak -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Allogene Therapeutics Inc Прогноза

Ценова цел

By TipRanks

431.9% нагоре

12-месечна прогноза

Среден 8.67 USD 431.9%

Висок 14 USD

Нисък 5 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Allogene Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на Allogene Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.18 / 1.69Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Настроение

By Acuity

151 / 352 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.